Lilly posted 48% year-over-year revenue growth and increased its incretin market share edge over Novo Nordisk, but the Danish firm continues to win the oral GLP-1 fight with Wegovy pill.
Lilly posted 48% year-over-year revenue growth and increased its incretin market share edge over Novo Nordisk, but the Danish firm continues to win the oral GLP-1 fight with Wegovy pill.